Literature DB >> 7237385

A new prognostic classification of chronic lymphocytic leukemia derived from a multivariate survival analysis.

J L Binet, A Auquier, G Dighiero, C Chastang, H Piguet, J Goasguen, G Vaugier, G Potron, P Colona, F Oberling, M Thomas, G Tchernia, C Jacquillat, P Boivin, C Lesty, M T Duault, M Monconduit, S Belabbes, F Gremy.   

Abstract

Survivals of two series of CLL patients (99 from a retrospective series and 196 from a prospective series) were studied separately. The three main staging systems (Rai, Binet, Rundles) agreed well, but as far as survival is concerned, too many stages are defined. The authors performed a Cox multivariate analysis of survival in order to isolate important prognostic factors at diagnosis and to use them to build a simple three-stage classification. Thrombopenia and anemia appeared as the most important risk factors. Among the nonanemic and nonthrombopenic patients, the number of involved areas was clearly related to prognosis in the authors' two series. This study allowed the authors to propose a new classification in three prognostic groups. Group C: anemia (Hb less than 10 g) and/or thrombopenia (platelets less than 100,000/mm3); about 15% of the patients; median of 2 years. Group B: no anemia, no thrombopenia, three or more involved areas (counting as one each of the following: axillary, cervical, inguinal, lymph nodes, whether unilateral or bilateral, spleen and liver); about 30% of patients; median of 7 years. Group A: no anemia, no thrombopenia, less than three involved areas; about 55% of patients; the survival of this group does not seem different from that of the French population of the same age and sex distribution. This three-stage classification only requires clinical examination and routine hemogram, has a good prognostic value which was confirmed on the series of Montserrat and Rozman (146 patients), and should therefore be helpful in planning new clinical trials.

Entities:  

Mesh:

Year:  1981        PMID: 7237385     DOI: 10.1002/1097-0142(19810701)48:1<198::aid-cncr2820480131>3.0.co;2-v

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  270 in total

1.  B-cell chronic lymphocytic leukemia risk in association with serum leptin and adiponectin: a case-control study in Greece.

Authors:  Maria Dalamaga; Bradley H Crotty; Jessica Fargnoli; Evangelia Papadavid; Antigoni Lekka; Maria Triantafilli; Konstantinos Karmaniolas; Ilias Migdalis; Amalia Dionyssiou-Asteriou; Christos S Mantzoros
Journal:  Cancer Causes Control       Date:  2010-05-08       Impact factor: 2.506

2.  miR-181b is a biomarker of disease progression in chronic lymphocytic leukemia.

Authors:  Rosa Visone; Angelo Veronese; Laura Z Rassenti; Veronica Balatti; Dennis K Pearl; Mario Acunzo; Stefano Volinia; Cristian Taccioli; Thomas J Kipps; Carlo M Croce
Journal:  Blood       Date:  2011-06-02       Impact factor: 22.113

Review 3.  Current and developing chemotherapy for CLL.

Authors:  Emili Montserrat
Journal:  Med Oncol       Date:  2002       Impact factor: 3.064

Review 4.  Can prognostic factors be used to direct therapy in chronic lymphocytic leukemia?

Authors:  Leopold Sellner; Sascha Dietrich; Peter Dreger; Hanno Glimm; Thorsten Zenz
Journal:  Curr Hematol Malig Rep       Date:  2012-03       Impact factor: 3.952

5.  Risk categories and refractory CLL in the era of chemoimmunotherapy.

Authors:  Thorsten Zenz; John G Gribben; Michael Hallek; Hartmut Döhner; Michael J Keating; Stephan Stilgenbauer
Journal:  Blood       Date:  2012-03-06       Impact factor: 22.113

6.  White blood cell count at diagnosis and immunoglobulin variable region gene mutations are independent predictors of treatment-free survival in young patients with stage A chronic lymphocytic leukemia.

Authors:  Ilaria Del Giudice; Francesca Romana Mauro; Maria Stefania De Propris; Simona Santangelo; Marilisa Marinelli; Nadia Peragine; Valeria Di Maio; Mauro Nanni; Rita Barzotti; Francesca Mancini; Daniele Armiento; Francesca Paoloni; Anna Guarini; Robin Foà
Journal:  Haematologica       Date:  2010-12-29       Impact factor: 9.941

7.  Restoring the functional immunogenicity of chronic lymphocytic leukemia using epigenetic modifiers.

Authors:  Jason A Dubovsky; Daniel Wang; John J Powers; Emmanuel Berchmans; Matthew A Smith; Kenneth L Wright; Eduardo M Sotomayor; Javier A Pinilla-Ibarz
Journal:  Leuk Res       Date:  2010-09-22       Impact factor: 3.156

8.  Mechanism of action of SNS-032, a novel cyclin-dependent kinase inhibitor, in chronic lymphocytic leukemia.

Authors:  Rong Chen; William G Wierda; Sherri Chubb; Rachael E Hawtin; Judith A Fox; Michael J Keating; Varsha Gandhi; William Plunkett
Journal:  Blood       Date:  2009-02-20       Impact factor: 22.113

Review 9.  Fludarabine. A review of its pharmacological properties and therapeutic potential in malignancy.

Authors:  S R Ross; D McTavish; D Faulds
Journal:  Drugs       Date:  1993-05       Impact factor: 9.546

10.  Intravenous immune globulin in chronic lymphocytic leukaemia.

Authors:  H Gamm; C Huber; H Chapel; M Lee; F Ries; M A Dicato
Journal:  Clin Exp Immunol       Date:  1994-07       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.